Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: The objective of this study was to investigate the duration of R2* and R2 enhancement in murine liver in vivo after administration of a single dose of 3 different iron oxide-based contrast agents. MATERIALS AND METHODS: Murine liver R2* and R2 were quantified longitudinally postadministration of 2.5 mgFe/kg ferumoxides, 2.5 mgFe/kg ferumoxytol, 2.5 or 5 mgFe/kg feruglose, or saline over 50 days. Changes in R2* and R2 were evaluated histologically using Perl's staining and by atomic absorption spectrometry. RESULTS: All 3 contrast agents significantly increased liver R2* and R2 4 hours after challenge. After 10 days, R2* and R2 for both the ferumoxides and ferumoxytol cohorts had recovered to saline control levels, whereas the faster R2* and R2 of the feruglose cohort was sustained and significantly faster than control at day 50. Histology revealed feruglose in both Kupffer and endothelial cells, whereas both ferumoxides and ferumoxytol were associated with the Kupffer cells. CONCLUSION: Compared with ferumoxides and ferumoxytol, feruglose exhibits prolonged R2* and R2 enhancement of murine liver.


Journal article


Invest Radiol

Publication Date





784 - 791


Animals, Contrast Media, Dextrans, Female, Ferrosoferric Oxide, Image Enhancement, Injections, Intravenous, Iron, Kinetics, Liver, Longitudinal Studies, Magnetic Resonance Imaging, Magnetite Nanoparticles, Metabolic Clearance Rate, Mice, Oxides